2024 articles
Strong capacity of differentiated PD‑L1 CAR‑modified UCB‑CD34+ cells and PD‑L1 CAR‑modified UCB‑CD34+‑derived NK cells in killing target cells and restoration of the anti‑tumor function of PD‑1‑high exhausted T Cells
Background: Using natural killer (NK) cells to treat hematopoietic and solid tumors has great promise. Despite their availability from peripheral blood and cord blood, stem
November 16, 2024
No Comments